POLISCOPE
Back to bills
Part ofAls →

The civic record

Read. Follow. Verify.
Passed

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

Last action · July 23, 2026: Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 466.Sponsors: Mike Quigley and 103 others

Introduced
Committee
Floor Vote
Passed
Law

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

Public stanceCommunity reactions are separate from the official record and reporting.

What This Bill Would Do

This bill extends federal funding and research programs for Amyotrophic Lateral Sclerosis (ALS) through 2031. It also introduces new requirements for clinical trial data sharing and mandates a comprehensive FDA report on progress in treating rare neurodegenerative diseases.

Why it matters

This legislation ensures the continuation of federal ALS research grants and regulatory programs through 2031, impacting the timeline for drug development and the availability of clinical trial data for patients and researchers.

Who It Would Affect

Groups the bill's text would affect if enacted, as described in the record. Being affected is not a position for or against it.

Directly affected

ALS patients and families

The bill dictates the timeline and regulatory framework for research into therapies for their condition.

Directly affected

Pharmaceutical manufacturers

Companies conducting ALS clinical trials must share interim data with the FDA to qualify for grant renewals.

Directly affected

Food and Drug Administration

The agency is tasked with new reporting requirements and oversight duties regarding clinical trial data.

Key Facts

  • Extends the authorization of the Accelerating Access to Critical Therapies for ALS Act from 2026 to 2031.
  • Requires the FDA to assess clinical trial enrollment data when reviewing grant renewal applications for investigational drugs.
  • Mandates that manufacturers share interim clinical trial data with the FDA to facilitate grant renewal assessments.
  • Expands the definition of 'phase 3' clinical trials to include combined phase 2/3 trials and planned trials not yet enrolling participants.
Show all 8 facts
  • Requires the FDA Commissioner to publish an updated action plan for ALS and other rare neurodegenerative diseases within one year of enactment.
  • Requires the FDA to report on the implementation and outcomes of the 2022 Action Plan for Rare Neurodegenerative Diseases.
  • Mandates a GAO report on the program's progress to be submitted to Congress within four years of enactment.
  • Expresses a Sense of Congress that funds should be directly appropriated to carry out the Act's provisions.

Frequently Asked Questions

How long will this program be extended?
The provisions of the Act are extended through fiscal year 2031.
What new information must drug manufacturers provide?
Manufacturers seeking grant renewals must share interim clinical trial data with the FDA so the agency can assess patient enrollment status.
When will the public see a report on these efforts?
The FDA must publish an updated action plan and report on the 2022 Action Plan within one year of the bill's enactment.

What else do you want to know?

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Where This Stands

Currently passed chamber. The next step in the legislative lifecycle is Law.

Procedural history

18 actions
  1. Jul 23, 2026Senate
    Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 466.
  2. Jul 22, 2026House
    Motion to reconsider laid on the table Agreed to without objection.
  3. Jul 22, 2026HouseFloor
    On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
  4. Jul 22, 2026HouseFloor
    Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
  5. Jul 22, 2026House
    Considered as unfinished business. (consideration: CR H5159)
  6. Jul 20, 2026House
    At the conclusion of debate, the chair put the question on the motion to suspend the rules. Mr. Guthrie objected to the vote on the grounds that a quorum was not present. Further proceedings on the motion were postponed. The point of no quorum was considered as withdrawn.
Show 12 earlier actions
  1. Jul 20, 2026House
    DEBATE - The House proceeded with forty minutes of debate on H.R. 8205.
  2. Jul 20, 2026House
    Considered under suspension of the rules. (consideration: CR H4652-4654; text: CR H4653)
  3. Jul 20, 2026House
    Mr. Guthrie moved to suspend the rules and pass the bill, as amended.
  4. Jul 9, 2026House
    Placed on the Union Calendar, Calendar No. 637.
  5. Jul 9, 2026House
    Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-733.
  6. May 21, 2026HouseCommittee
    Ordered to be Reported (Amended) by the Yeas and Nays: 46 - 0.
  7. May 21, 2026House
    Committee Consideration and Mark-up Session Held
  8. May 13, 2026House
    Forwarded by Subcommittee to Full Committee by Voice Vote.
  9. May 13, 2026House
    Subcommittee Consideration and Mark-up Session Held
  10. Apr 6, 2026HouseCommittee
    Referred to the Subcommittee on Health.
  11. Apr 6, 2026HouseCommittee
    Referred to the House Committee on Energy and Commerce.
  12. Apr 6, 2026HouseIntroduced
    Introduced in House

Version history

Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.

View official text →

Full breakdown

Who this bill affects and the strongest case for and against it, written only from the bill’s own text.

Sponsors

Show 99 more sponsors
Eleanor NortonHouse · District 0DemocraticCosponsorNo profile match
Adelita GrijalvaHouse · District 7DemocraticCosponsorNo profile match
Analilia MejiaHouse · District 11DemocraticCosponsorNo profile match

Discoveries

1 pattern noticed across the record

Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.

policy shift95% confidence

Increased Data Transparency

The bill shifts from simple funding authorization to requiring active sharing of interim clinical trial data between manufacturers and the FDA.

Connected Entities

Mr. Calvert, Food and Drug Administration, Mr. Quigley and 1 more
PersonMr. Calvert“Member of the House of Representatives who co-sponsored the bill.”Map →
OrganizationFood and Drug Administration“Responsible for implementing research programs and publishing the required actio”Map →
PersonMr. Quigley“Member of the House of Representatives who introduced the bill.”Map →
OrganizationGovernment Accountability Office“Required to submit a report on the program's progress within four years.”Map →

Sources

Open source document

www.congress.gov

Analysis Score

0–100
  • Significance75
    How much this matters to a regular citizen
  • Controversy10
    Intensity of disagreement among stakeholders
  • Entertainment5
    Compellingness for a non-policy-wonk reader
  • Buzz20
    Current news / social attention level

Publisher tools

Share or embed this record

POLISCOPE publisher tools

Share or embed this record